Cancers familiaux et cancers hÃ©rÃ©ditaires - Institut Jules Bordet ...

More documents

Recommendations

Info

ASCO 2005HIGHLIGHTS OF THE 2005 ASCO ANNUAL MEETINGGilberto de Castro Jr., Ahmad Awada,Clinique d’Oncologie Médicale, Institut Jules BordetAmong the more than 9500 abstracts published in the Proceedings of the 2005Annual Meeting of the American Society of Clinical Oncology, we present those whorepresent a new standard of care of solid tumors. The first author and the number ofeach abstract are mentioned. The reader is invited to consult the original abstractspublished in J Clin Oncol 23 (16S).Breast CancerLeach (520): Magnetic resonance imaging (MRI)was found to be more sensitive than conventionalmammography in breast cancer (BC) detectionin high-risk patients (pts) and specifically in thesubgroup of BRCA1 carriers, suggesting that MRImust be added to the screening of BC in thisgroup of pts.Baxter (516):The rate of invasive ipsilateral BC at8 years in 10,034 women diagnosed with ductalcarcinoma in situ (DCIS) submitted to lumpectomyonly was 6.2% versus (vs.) 2.7% in thosetreated also by radiation therapy (RT, HR 0.43),supporting the routine use of RT after lumpectomyfor DCIS.Paik (510): Using the 21-gene recurrence score(RS) assay Oncotype DX, it was showed that thebenefit of adjuvant treatment with tamoxifenin terms of better 10-year distant-recurrencefree survival in the study NSABP B-14 was confinedto the pts with low (RS
Genitourinary cancerEscudier (4510): BAY 43-9006 is an oral inhibitor ofRaf-kinase and also has important antiangiogenicactivity, inhibiting VEGFR-2, PDGFR, Flt-3 andc-kit receptors. 769 pts with renal cell carcinoma(MSKCC low or intermediate risk groups) with oneprevious treatment were enrolled in a phase IIIrandomized, placebo-controlled trial evaluatingBAY 43-9006 400 mg twice a day, continuously.Median PFS was 24 weeks for BAY vs. 12 weeks forplacebo (p
Page 4: ABORDET-IRIS — ERASME — WÉDITO
Page 7 and 8: ABORDET-IRIS — ERASME — WVincen
Page 9 and 10: ABORDET-IRIS — ERASME — WSERVIC
Page 11 and 12: ABORDET-IRIS — ERASME — WFig. 1
Page 13: ÉTUDES EN COURSProtocoles de vacci
Page 16 and 17: INFORMATION SCIENTIFIQUEL’étude
Page 18 and 19: POLITIQUE ET SANTÉNouveaux traitem
Page 20 and 21: RECHERCHEBiology of bronchial preca
Page 23 and 24: l’erlotinib (Tarceva®, inhibiteu
Page 25 and 26: Grade 1 Grade 2 Grade 3GG1GG310.50-
Page 27: moins 1 âgé de moins de 50 ans au
Page 32: P.P. 10.000IU 107,45a AhfP.P. 10.00

Cancers familiaux et cancers hÃ©rÃ©ditaires - Institut Jules Bordet ...

Create successful ePaper yourself

Delete template?

Save as template?